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ABSTRACT
Background Epidemiology of Neisseria meningitidis 
has been changing since the introduction of universal 
vaccination programmes against meningococcal 
serogroup C (MenC) and meningococcal serogroup B 
(MenB) has now become dominant. This study aimed 
to analyse the cases reported in institutional data 
recording systems to estimate the burden of invasive 
meningococcal diseases (IMDs) and assess the 
effectiveness of surveillance in Veneto region (Italy).
Methods Analysis was performed from 2007 to 2014 
on data recorded in different systems: Mandatory 
Notification System, National Surveillance of Invasive 
Bacterial Diseases System and Laboratories Surveillance 
System (LSS), which were pooled into a combined 
surveillance system (CSS) and hospital discharge 
records (HDRs). A capture-recapture method was used 
and completeness of each source estimated. Number 
of cases with IMD by source of information and year, 
incidence of IMD by age group, case fatality rate (CFR) 
and distribution of meningococcal serogroups by year 
were also analysed.
Results Combining the four data systems enabled 
the identification of 179 confirmed cases with IMD, 
achieving an overall sensitivity of 94.7% (95% CI: 90.8% 
to 98.8%), while it was 76.7% (95% CI: 73.6% to 80.1%) 
for CSS and 77.2% (95% CI: 74.1% to 80.6%) for HDRs. 
Typing of isolates was done in 80% of cases, and 95.2% 
of the typed cases were provided by LSS. Serogroup 
B was confirmed in 50.3% of cases. The estimated 
IMD notification rate (cases with IMD diagnosed and 
reported to the surveillance systems) was 0.48/100 
000 population, and incidence peaked at 6.2/100 000 
in children aged <1 year old (60.9% due to MenB), and 
increased slightly in the age group between 15 and 19 
years (1.1/100 000). A CFR of 14% was recorded (8.7% 
in paediatric age).
Conclusions Quality of surveillance systems relies on 
case ascertainment based on serological characterisation 
of the circulating strains by microbiology laboratories. All 
available sources should be routinely combined to improve 
the epidemiology of IMD and the information used by 
public health departments to conduct timely preventive 
measures.
INTRODUCTION
Neisseria meningitidis is the organism respon-
sible for invasive meningococcal diseases 
(IMD) worldwide. IMD can affect all ages and 
have numerous serious manifestations, the 
most common being meningitis, septicaemia 
or a combination of the two.1
Of all N. meningitidis serogroups identified, 
five are the most often responsible for IMD 
(serogroups A, B, C, Y and W), but the epide-
miology of IMD varies around the world and 
different geographical areas are classified as 
having a low, moderate or high endemicity.2 3 
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Strengths and limitations of this study
 ► In this study, a record linkage analysis on several 
different surveillance systems showed that the 
quality of epidemiological information on invasive 
meningococcal disease (IMD) can be improved 
by integrating it with specific microbiological 
laboratory-based data.
 ► Our results suggest that a routine pooling of all 
available data sources is needed to overcome any 
surveillance gaps. This approach is recommended 
in order to provide guidance for decision-makers 
on crucial public health policies and achieve an 
effective control of meningococcal disease.
 ► Our analysis also indicates that microbiological 
data are suboptimally recorded by conventional 
surveillance systems. For this reason, the availability 
of data generated by laboratories is crucial for 
clarifying the temporal and spatial distribution of the 
circulating meningococcal serogroups.
 ► To provide a complete surveillance assessment, our 
investigation requires a more in depth analysis of 
supplementary data sources so that some clearer 
trends can be detected (ie, vaccination status or 
surveillance of vaccine failure, as well as antibiotic 
resistance).
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confirmed IMD is 0.75/100 000 population (range: 0.09–
1.99/100 000 population). During the period 2008–2012, 
the European Centre for Disease Control included Italy 
among the European countries with a low incidence of 
IMD, given its notification rate of 0.26/100 000 popula-
tion.4
The distribution of the meningococcal serogroups 
varies considerably, both geographically and temporally, 
around the world. Meningococcal serogroup B (MenB) 
dominates in many parts of the world, including Europe, 
and the inclusion of a conjugated vaccine for meningo-
coccal serogroup C (MenC) in the routine vaccination 
programmes of several European countries has led to a 
drastic reduction in the cases of IMD caused by MenC, 
leaving the countries concerned with a predominance of 
IMD due to MenB.1
Aside from MenB and MenC, other serogroups (A, Y 
and W) are still important in areas of Europe and close 
to its borders, and they can be responsible for epidemic 
disease.5 Recent evidence indicates that meningococcal 
serogroup Y (MenY) has continued to increase in 
northern Europe and the proportion of IMD attributable 
to MenY remains high in Scandinavian countries, ranging 
from 26% to 51%.6
An analysis of consolidated data (referring to 2014) 
shows that the incidence of IMD in Italy has remained 
stable in recent years, apart from an unexpected increase 
in the cases of MenC in young adults was reported in 2015 
due to a cluster in Tuscany, which recurred in the early 
months of 2016. Immunisation campaigns have been 
implemented as a result, continuously adapting them to 
the evolution of the epidemiological situation, and IMD 
surveillance activities have been enhanced.7 MenC is the 
second most common serogroup in Italy (accounting for 
31% of the 115 cases with a known serogroup in 2014) 
after MenB (with 48% of the 115 cases in 2014), while 
MenY is the third cause of meningococcal infection (13% 
of the serogroups typed in 2014).8
Based on 2014 data, in Veneto (northeast Italy) the 
incidence of IMD is 0.35/100 000 population. The intro-
duction of a universal free infant vaccination programme 
against MenC has changed the local epidemiology, 
making MenB dominant instead of MenC.9
Surveillance data can provide information on the 
frequency of IMD and the distribution of the circulating 
serogroups (on which vaccination programs are based). 
In times when the incidence of these diseases is declining, 
a complete and timely reporting of cases of infection is 
essential for prompt and effective clinical and public 
health interventions, and for epidemiological investiga-
tions, postexposure prophylaxis, and any vaccination of 
members of households in the case of individuals infected 
by a vaccine-preventable serogroup.10 11
However, the real burden of IMD is not known for 
many parts of the world due to inadequate epidemiolog-
ical surveillance schemes.12 This paper analysed the cases 
reported in the various institutional public health data 
recording systems in order to: assess the outcome of action 
taken to monitor invasive meningococcal infection in the 
Veneto region of northeastern Italy; estimate the inci-
dence of IMD; establish the distribution of the circulating 
meningococcal serogroups and test the completeness of 
the different sources considered.
Materials and methods
We considered the data available from four different data 
sources in Veneto on the surveillance of invasive bacterial 
diseases over the years from 2007 to 2014.
The cases considered in our analysis were all laborato-
ry-confirmed, that is, they involved individuals meeting 
the laboratory criteria with at least one of the following: 
isolation of N. meningitidis from a normally sterile site, 
including purpuric skin lesions; detection of N. menin-
gitidis nucleic acid from a normally sterile site, including 
purpuric skin lesions; detection of N. meningitidis antigen 
in cerebrospinal fluid (CSF) and detection of Gram-neg-
ative-stained diplococcus in CSF.13
The different data systems analysed were the following:
1. the Mandatory Notification System (MNS) of the 
Italian Ministry of Health; physicians are obliged to 
report all cases of invasive meningococcal infection 
to the National Health Service within 24 hours 
and, after being confirmed, cases are documented 
in the surveillance system. The MNS database 
contains a unique patient identification number, 
demographic details and the dates of notification, 
first symptoms and diagnosis.
2. The National Surveillance of Invasive Bacterial 
Diseases System (NSS) was implemented in 1994 by 
the Istituto Superiore di Sanità (ISS) to collect data on 
Neisseria causing IMD. Hospital physicians report 
cases to their local Public Health Unit. The NSS 
contains a unique patient identification number, 
demographic details, the name of the laboratory 
submitting the strain, the dates of sample collection 
and receipt and the outcome of N. meningitidis 
typing.
3. The Laboratories Surveillance System (LSS) was 
extended to cover all invasive bacterial diseases 
(including those due to N. meningitidis) in Veneto 
in 2007; it is based on data collected by hospital and 
Local Health Authority microbiology laboratories. 
The microbiology laboratorians report all suspected 
clinical cases of IMD to the Regional Epidemiology 
Centre and concurrently send biological samples 
to the Regional Reference Laboratory for culture 
confirmation and serotyping of the isolates.
The records of these three data sources were linked after 
constructing an unequivocal personal code (patient’s 
date of birth, gender, post al code/place of residence 
and initials). All further linkages were checked manually 
and, if plausible for all variables, they were assumed to be 
correct and recorded routinely in a single database, the 
combined surveillance system (CSS).
As a fourth data source, we considered the regional 
archives of hospital discharge records (HDRs), identifying 
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all hospital stays that contained a principal and/or 
secondary diagnosis coded as  036. xx (meningococcal 
infection) according to the International Classification of 
Diseases, Ninth Revision, Clinical Modification.
A capture-recapture method, as described by De Greeff 
et al, was used and certain crucial assumptions were 
made.14 First, a patient listed in both the CSS and the 
HDR databases had to be matched as one and the same 
patient; second, the same population and time period 
had to be covered by the databases; third, reports of all 
data sources must be made independently and last, all 
cases had to have an equal probability of being selected 
in a given source.14–16 The contribution of the single data 
sources was also assessed.
The first step of the capture-recapture analysis involved 
analysing the MNS, NSS and LSS data to estimate the 
number of cases not registered, and thereby obtain the 
total number of cases of IMD based on the degree of 
overlap between the different sources. The models were 
compared with the likelihood ratio test (G2), the Akaike 
Information Criterion [AIC=G2–2(df)] and the Bayesian 
Information Criterion (BIC). The best-fitting model was 
selected from among eight different log-linear models, 
choosing the one with the lowest G2 and AIC.14 After 
constructing the CSS, the second step involved applying 
the capture-recapture method to the CSS and the HDRs 
to compare the completeness of Veneto’s routine data 
collection system with that of the hospitalisation rate 
for specific meningococcal diseases. The completeness 
(as a percentage) of each data source was estimated by 
dividing the number of cases of meningococcal disease 
observed for each source by the number of cases resulting 
from the capture-recapture estimate. The incidence of 
IMD (per 100 000 population) was estimated considering 
the number of confirmed cases as a proportion of the 
region’s resident population (provided by the Veneto 
Regional Authority’s statistics office). The number of 
IMD-related deaths was obtained from the data available 
for this study (all sources) and the case fatality rate (CFR) 
was calculated. The distribution of the cases of IMD by 
serogroup was assessed by analysing the CCS data alone.
This study complied with the Declaration of Helsinki 
and with Italian privacy law (Legislative decree no 
196/2003) on the protection of personal data. Informed 
consent and approval from the local ethics committee 
were unnecessary because the information involved is 
routinely recorded for surveillance purposes and treated 
in anonymous form. Moreover, resolution no 85/2012 of 
the Italian Guarantor on the protection of personal data 
allows for personal data to be processed for the purposes 
of medical, biomedical and epidemiological research, 
and confirms that data on people’s state of health may be 
used in aggregate form in scientific studies.13 17
RESULTS
During the interval between 2007 and 2014, there were 
133 cases of IMD notified to the MNS, 122 to the NSS and 
104 to the LSS. Combining the three surveillance systems 
(CSS) identified 145 cases recorded in at least one of the 
three sources, and 56.6% (of them 82/145) were listed in 
all three (figure 1). All patients identified by the surveil-
lance systems had been hospitalised.
The log-linear model with the lowest G2, AIC and BIC 
included the interaction between the MNS, NSS and LSS 
sources, and estimated a total of 146 (95% CI: 145 to 152) 
cases of IMD (table 1). The completeness of the CSS was 
estimated at 99.3% (95% CI: 95.4% to 100%), while 
for the MNS it was 91.1% (95% CI: 87.5% to 91.7%), 
which was >83.5% obtained for the NSS (95% CI: 80.3% 
to 84.1%) or the 71.2% for the LSS (95% CI: 68.4% to 
71.7%).
Our record-linkage analysis between the CSS and HDR 
data identified 179 cases of invasive bacterial disease 
with a specific diagnosis of N. meningitidis. Altogether, 
112 cases (62.6%) were recorded by both information 
sources, 33 (18.4%) only by the CSS and 34 (19.0%) 
only in the HDRs. Capture-recapture analysis estimated 
189 cases, calculating a completeness of 94.7% (95% CI: 
90.8% to 98.8%) for the CSS and HDRs combined, while 
the two sources separately reached figures of 76.7% (95% 
CI: 73.6% to 80.1%) for the CSS and 77.2% (95% CI: 
74.1% to 80.6%) for the HDRs.
The 33 cases emerging from the CSS, but not from the 
single databases (MNS, NSS and LSS), were also found 
in the HDRs, but without any indication of a principal 
or secondary diagnosis of meningococcal disease. The 
contribution of the CSS alone increased during the 
period of observation, rising from 7.5% in 2007 to 38.9% 
in 2014.
All N. meningitidis were laboratory-confirmed, but the 
serogroup was only typed in 80.0% of cases (116/145). 
The serogroup was available for 95.2% of the cases 
Figure 1 Venn diagram showing the number and 
percentage of cases of invasive meningococcal disease 
identified by three sources: the Mandatory Notification 
System, the National Surveillance of Invasive Bacterial 
Diseases System and the Laboratories Surveillance System 
in Veneto from 2007 to 2014.
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recorded in the LSS (99/104), while five meningococcal 
strains were found to be non-vital. The serogroup was also 
available for 41.5% (17/41) of the cases with IMD identi-
fied by the MNS and NSS surveillance systems.
Altogether, 50.3% (73/145) of the cases identified by 
the CSS were confirmed as MenB, 18.6% (27/145) were 
MenC, 8.3% (12/145) were MenY/W and 2.1% (3/145) 
were meningococcal group A.
The overall notification rate for IMD was 0.48/100 000 
population (the CSS accounted for 0.39/100 000). 
Figure 2 shows the estimated incidence of serogroups B 
and C, and also of the other, less common N. meningit-
idis serogroups (A, Y and W) isolated during the years of 
observation.
The incidence of IMD by age group, based on the cases 
notified, showed a peak for children <12 months old, with 
6.2 cases per 100 000 population (CSS: 5.4/100 000), and 
a second, much smaller rise in the disease’s incidence 
among the age group between 15 and 19 years, with 1.1 
per 100 000 population (CSS: 0.9/100 000). Among the 
children <12 months of age, 60.9% of the cases were 
attributable to MenB, with a specific rate of 3.8/100 000. 
Among children aged 1–4 years, the specific rate of 
MenB was 1.8/100 000, accounting for 70.0% of all cases. 
Figure 3 shows the incidence of meningococcal disease by 
age group and serogroup.
Invasive meningococcal disease proved lethal in 25 
cases over the 8 years considered. The overall CFR was 
14.0% and increased with age, from 8.7% in the <1 year 
olds to 18.4% in the >45 year olds. In the N. meningitidis 
serogroup, 7 of the patients who died were infected with 
MenC (mean age 36.6 years; range 10-72; median 33 
years), 4 of them during an epidemic cluster occurring in 
Veneto in 2007-2008), while 12 had MenB (mean age 15.7 
Table 1 Log-linear models fitted to three sources of data on invasive meningococcal disease and the estimated number of 
meningococcal cases in Veneto (2007-2014)
Model df G2 p-Value AIC BIC x^ N^ 95% CI
A B C 3 4.43 0.22 −1.57 −1.41 0 145 145 to 148
A B C (AB) 4 0.38 0.83 −3.62 −3.52 1 146 145 to 152
A B C (AC) 4 4.43 0.11 0.43 0.54 0 145 145 to 149
A B C (BC) 4 4.42 0.11 0.42 0.53 0 145 145 to 148
A B C (AB) (AC) 5 0.1 0.76 −1.9 −1.85 2 147 145 to 159
A B C (AB) (BC) 5 0.31 0.58 −1.69 −1.64 1 146 145 to 154
A B C (AC) (BC) 5 4.42 0.04 2.42 2.48 0 145 145 to 149
A B C (AB) (AC) (BC) 6 0 1 0 0 2 147 145 to 167
A, Mandatory Notification System; AIC, Akaike Information Criterion; B, National Surveillance of Invasive Bacterial Diseases System; 
BIC, Bayesian Information Criterion; C, Laboratories Surveillance System; G2, likelihood ratio test statistic; N^: estimate of the total cases; x^, 
estimate of the total cases not reported to any source. Bold values indicate the best-fitting model.
Figure 2 Annual notification rate per 100 000 population for Neisseria meningitidis serogroups B and C, and the other less 
common serogroups (A, Y and W) in the years 2007-2014, estimated from the Combined Surveillance System.
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years; range 0-78; median 2 years), and 8 of them (67%) 
were children <5 years old, and a 45-year-old patient was 
infected with MenY. Typing was not available for the 
remaining five patients (20%) (mean age 64.0 years; 
range 20-94; median 71 years). For MenB alone, the CFR 
was 16.4% overall and 14.3% for infants.
DISCUSSION
Estimating the cases of IMD with the capture-recapture 
method, after pooling three data sources into the CSS, 
gave an overall completeness of 99.3%, which became 
94.7% after linkage with the HDRs. When the CSS and 
HDRs were considered separately, they were 76.7% 
and 77.2% complete, respectively. By comparison with 
the results of similar studies,14 15 our findings show 
that a greater degree of completeness was achieved by 
combining the CSS data with the HDRs.
A limitation of the capture/recapture method lies in 
the lack of a full independence between the sources that 
represent an assumption of the application of method-
ology. In our analysis of the CSS, which included data 
from three sources, this assumption was not crucial 
because interaction terms can be incorporated in the 
regression models to adjust for source dependence, while 
the two sources are independent in the two source (CSS 
and HDR) capture/recapture.18
Our assessment of the effectiveness of IMD surveillance 
in Veneto (northeastern Italy) reveals an under-reporting 
phenomenon, despite the clinical severity of these 
diseases. This goes to show that Italy’s national surveil-
lance systems (MNS and NSS) are not always notified of 
every case.19
Based on the data in the national integrated surveil-
lance systems (MNS and NSS) and the LSS, the incidence 
of IMD was estimated at 0.39/100 000 for the years 
2007-2014. Linkage between these sources returned a 
higher rate than the one estimated for Italy in recent 
years (0.28/100 000),20 and for infants <1 year old it was 
5.4/100 000, as opposed to the estimated 3.6/100 000. 
This discrepancy is probably attributable partly to the 
endemic epidemiological profile of the distribution of N. 
meningitidis in the geographical area considered in this 
study, but also to a different sensitivity of the surveillance 
systems in recording the total number of cases of IMD, 
which makes it difficult to reliably establish the burden of 
these diseases. Our findings show that the availability of 
appropriate diagnostic services (ie, microbiology labora-
tories) is crucial for an accurate epidemiological picture 
and for identifying the circulating serotypes on which to 
base prevention policies.
Thirty-four cases of IMD were only identifiable from 
the HDRs, making it seem important to use this data 
source to complete the epidemiological picture of IMD. 
The possibility of coding errors cannot be ruled out, 
however, so the HDR dataset can clearly be used to estab-
lish the frequency of a disease only after the data they 
contain have undergone critical review. For the years of 
our analysis (2007-2014), the HDRs containing a diag-
nosis of meningococcal infection identified much the 
same number of cases of IMD as the databases of the 
three surveillance systems combined. Errors relating to 
inappropriately recorded discharge diagnoses or misdi-
agnoses are more likely in the hospital records, however, 
whereas this was not expected in the CSS because all the 
cases were laboratory-confirmed.
Our findings indicate that HDRs should not be consid-
ered exhaustive as a sole source of information because 
they failed to identify approximately 18% of the cases of 
IMD. The cases recorded by the CSS concerned patients 
who had been admitted to hospital, and data linkage 
pinpointed some whose HDRs made no specific mention 
of meningococcal infection. There is, therefore, a need 
Figure 3 Incidence of invasive meningococcal disease per 100 000 population by age group and serogroup in Veneto during 
the period 2007-2014. The data came from the three pooled sources (Combined Surveillance System) and from the hospital 
discharge records.
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to improve the accuracy of HDR data. Another weakness 
of HDRs for the purpose of monitoring IMD stems from 
their failure to provide any information on the typing 
of the N. meningitidis strains, which prevents a thorough 
investigation into the infection’s epidemiological profile.
Judging from our data, N. meningitidis typing was 
done for 80.0% of the IMD isolates obtained, with an 
important contribution—for meningococcal surveillance 
purposes—coming from the LSS. In fact, typing was avail-
able for 95.2% of the cases identified by means of the 
LSS, as compared with 41.4% of the cases in the MNS 
and NSS. LSS was the system with the lowest percentage 
of completeness, so it is crucially important to raise the 
proportion of culture-confirmed cases and integrate its 
findings with the data from other sources.
A further contribution to clarifying the epidemiological 
picture of IMD can come from serotyping by real-time 
PCR, which is significantly more sensitive than culture 
and enables a diagnosis in culture-negative samples. This 
approach should be included in routine surveillance 
programs.21
From the public health standpoint, the percentage 
of cases missing from the CCS, despite the notification 
of cases of IMD being mandatory in Italy, may nega-
tively affect the ability of the national health service to 
conduct epidemiological surveys and adopt appropriate 
preventive measures. Postexposure prophylaxis and the 
vaccination of people coming into contact with cases with 
IMD are very important. The rate of secondary disease 
for close contacts is highest during the first few days after 
the onset of the disease in the primary patient, and anti-
microbial chemoprophylaxis should be administered as 
soon as possible (ideally within 24 hours after the case has 
been identified); chemoprophylaxis administered for >14 
days after the onset of illness in the index case patient 
is probably of little or no value.22 In this setting, physi-
cians’ reporting of suspected cases needs to be improved 
in order to ensure a better and more extensive public 
health response. Early warning systems based on emer-
gency rooms could also be important for speeding up the 
identification of cases.11
To improve clinicians’ sensitivity to the need to report 
IMD promptly, some authors suggest using ad hoc 
reminders, and posting lists of diseases that should be 
reported and guidelines on the reporting procedures in 
emergency rooms.23
Isolate analysis indicated that MenB was the organism 
most often responsible for IMD in our sample, especially 
among children <1 year old. We identified a reduction in 
the number of cases involving MenC, and this is probably 
related to the high vaccination coverage rate achieved in 
this region.24
Meningococcal C vaccination was introduced in Veneto 
in 2008, actively inviting age cohorts at 13 months, 6 
years and 15 years old, and reaching a coverage of about 
90.0% since 2010.24 To further improve the programme, a 
multicomponent vaccine against MenB was introduced in 
2015, and infants were actively invited, but coverage data 
are not yet available. Further analyses are needed to assess 
the effects of introducing meningococcal B vaccination, 
as done for the type C vaccine.
Our reported CFR are fairly comparable with those of 
other European countries, where the CFRs range from 
5.3% to 12.5%.25–29 Our data identify a higher CFR (14%), 
but this could relate partly to different data sources used 
to confirm mortality: laboratory base case data versus 
capture-recapture method including also HDRs, as in our 
study. In addition, the circulation in our geographical 
area of serotypes such as the ST-11 meningococci types 
(a hyper-virulent clone) leads to a high fatality rate, as 
isolated in the epidemic cluster of 2008 included in our 
results. An accurate serotyping achieved by involving 
microbiologists allows calculating the CFR for singular 
meningococcal serogroups.30–32 When MenB was consid-
ered alone in our analysis, the CFR was 16.4%, a figure 
similar to the one reported in the Italian paediatric popu-
lation.21
It is impossible to say whether any patients with IMD 
died before reaching hospital. The time frame of these 
diseases is very short, but should be long enough to 
enable hospitalisation (deaths usually occur 24 hours 
after the first symptoms appear).33 A further development 
could involve making the mortality database part of the 
surveillance system.
Finally, from a quantitative point of view (number of 
cases of disease), the surveillance systems operating in 
Veneto and the HDRs identify cases of IMD approxi-
mately equally well, but the routine pooling of all available 
data sources affords a better epidemiological picture of 
IMD. The better quality of the data available from our 
surveillance systems is thanks mainly to the serological 
characterisation of the circulating meningococcal strains 
provided by microbiology laboratories, and molecular 
typing reduces the underestimation of cases resulting 
from cultures alone.34
The routine integration of different databases to 
build a single, web-based system in which all the actors 
(physicians, laboratorians, public health workers, emer-
gency room workers and so on) can promptly input all 
the information on IMD at their disposal is crucial to the 
successful implementation and assessment of targeted 
prevention strategies and fundamental to public health 
decision-making.
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